Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SR-2508

Known as: SR 2508, SR2508 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
PURPOSE To report the survival results from a previous Phase I study of etanidazole (ETA) and radiotherapy in patients with… Expand
Is this relevant?
1994
1994
The pharmacokinetics of cyclophosphamide (CP) and several important metabolites was studied in detail in six patients receiving… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
1987
1987
Complete pharmacological data from 71 patients treated on the phase I trial of SR 2508 were analyzed to see if the dose-limiting… Expand
  • table 1
  • figure 2
  • figure 1
Is this relevant?
1986
1986
Sixty-five patients were entered on the long schedule of the Phase I trial of SR-2508. The planned total doses ranged from 30 to… Expand
Is this relevant?
1985
1985
We have investigated the effect of extreme, prolonged hypoxia on the radiosensitivity of EMT6/SF cells in vitro. As cells were… Expand
Is this relevant?
1984
1984
Depletion of intracellular glutathione (GSH) can enhance misonidazole (MISO) radiosensitizing efficacy both in vivo and in vitro… Expand
Is this relevant?
1984
1984
From March 15, through August 31, 1983, 37 patients have been entered on the RTOG Phase I trial of SR-2508. The drug was given… Expand
Is this relevant?
1981
1981
Abstract Using a combination of toxicological, pharmacological and radiosensitization experiments on cells in vitro and tumors in… Expand
Is this relevant?
Highly Cited
1980
Highly Cited
1980
Ten 2-nitroimidazole radiosensitizers of electron affinity equal to that of misonidazole, but differing in their octanol:water… Expand
Is this relevant?
1980
1980
The behavior of three 2-nitroimidazole drugs of similar electron affinity to misonidazole but with varying octanol: water… Expand
Is this relevant?